Brief: Cipher Partner, Moberg Pharma Announces Approval For MOB-015 In The European Union

Cipher Pharmaceuticals

05/07/2023 12:26

July 5 (Reuters) - Cipher Pharmaceuticals Inc  CPH.TO :
    * CIPHER PARTNER, MOBERG PHARMA ANNOUNCES APPROVAL FOR
MOB-015 IN
THE EUROPEAN UNION
    * CIPHER - HOLDS EXCLUSIVE CANADIAN RIGHTS TO MOB-015, SEES
APPROVAL IN EUROPEAN UNION AS IMPORTANT STEP FORWARD TOWARDS
APPROVAL IN NORTH AMERICA
    * CIPHER - MOB-015 IS RECOMMENDED FOR NATIONAL APPROVAL IN
13
EUROPEAN COUNTRIES, WILL BE COMMERCIALIZED THROUGH PARTNERS SUCH
AS BAYER AND ALLDERMA
    * CIPHER PHARMACEUTICALS INC -  MOB-015 EXPECTED TO BE
LAUNCHED IN
NORDIC COUNTRIES SUCH AS SWEDEN DURING 2023

Source text for Eikon:  ID:nCNWNs367a 
Further company coverage:  CPH.TO 

 (Reuters.Briefs@thomsonreuters.com)